ONTARIO, Calif., Nov. 17, 1998 (PRIMEZONE) -- LifePoint, Inc. (OTC BB: LFPT), a developer of rapid, non-invasive testing products using saliva, announced that it has begun a program to communicate the Company's success to the investment community. Alan Stone & Company ("ASC"), www.AlanStone.com, was recently engaged as investor relations advisor to LifePoint and ASC will spearhead an active broker communication program to convey the Company's technological advancements, product development, financing success and growth potential.
LifePoint is an exciting development stage company in the medical device industry, which recently secured a $1 million institutional private equity placement. The financing will propel LifePoint's efforts to commercialize its unique patented flow immunosensor technology licensed from the US Navy. The flow immunosensor technology, when used in conjunction with saliva as a non-invasive test specimen using the Company's proprietary collection technology, will allow LifePoint to develop a broadly applicable non-invasive, rapid, on-site diagnostic test system. The first product under development is for the simultaneous detection of drugs of abuse and alcohol, with the ability to perform up to 10 tests simultaneously, in just a few minutes.
LifePoint's total available market for just this first product, estimated at over $750 million in 1998, and estimated to grow to $1 billion in 2002, is one of the single largest, individual product market opportunities in the worldwide, in-vitro diagnostic industry. The total available target markets for the products available during the five years after first product launch are over $1.6 billion. Most important, the markets are non-cyclical and recession resistant.
The technology has broad applicability to other medically important immunoassay and chemistry analytes, including long-term therapeutic monitoring, disease state testing, and wellness-health screening. Some of the potential diagnostic applications are: 1) emergency cardiac assessment, 2) screening for osteoporosis, cancer, and heart disease risk, and 3) identification of infectious diseases such as AIDS.
Ms. Linda Masterson, LifePoint's dynamic President and CEO, will be presenting LifePoint's accomplishments and the Company's outlook at the Equities Conference in New York City at 9:30 AM on November 19th. During her trip earlier that week, she will also be available to schedule private one-on-one meetings with market makers, portfolio managers, brokers and analysts interested in hearing LifePoint's story.
We invite you to review the enclosed most recent news release highlighting LifePoint's patent application for saliva collection and visit the Company's website at www.lifepointinc.com.
Please call Alan Stone & Company at 310.444.3940 with any questions about LifePoint and the upcoming Equities Conference at the Grand Hyatt Hotel in New York City on November 19that 9:30AM. Either Alan Stone or Tytus Bin will be happy to assist you or to schedule a meeting with the Company.
YOU ARE CORDIALLY INVITED TO MEET
LIFEPOINT, INC.
OTC BB SYMBOL: LFPT
www.lifepointinc.com
AND LISTEN TO THE MANAGEMENT PRESENTATION
at the EQUITIES FALL CONFERENCE
November 19th, 1998 9:30 AM
Luncheon @ 12:00 Noon
Grand Hyatt Hotel
in New York City
42nd Street @ Grand Central Terminal
LifePoint, Inc. is a development stage company focused on the commercialization of the flow immunosensor technology licensed from the Naval Research Laboratories. The patented flow immunosensor technology, when used in conjunction with saliva as a non-invasive test specimen using the Company's proprietary collection technology, will allow LifePoint to develop a broadly applicable non-invasive, rapid, on-site diagnostic test system. The first product under development is for the simultaneous detection of drugs of abuse and alcohol.
The technology has broad applicability to other medically important immunoassay and chemistry analytes, including long-term therapeutic monitoring, disease state testing, and wellness-health screening. Some of the potential diagnostic applications are: 1) emergency cardiac assessment, 2) screening for osteoporosis, cancer, and heart disease risk, and 3) identification of infectious diseases such as AIDS.
You will be able to meet LifePoint's President and CEO, Ms. Linda Masterson, who will be available at a breakout session and at lunch for informal meetings with analysts, portfolio managers, media, and other members of the investment community. Please contact us immediately if you are interested in additional details, and to register for the Equities Conference. For further information about the Company please contact Alan Stone & Company by phone (310) 444-3940, fax (310) 444-3941, or by email through our website. -0-